

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

Proposed Effective Date: January 5, 2026

Revisions are noted with a ~~strike through~~ for deletions and **bold and underline** for additions.

I. Requirements for Prior Authorization of Migraine Acute Treatment Agents

A. Prescriptions That Require Prior Authorization

Prescriptions for Migraine Acute Treatment Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Migraine Acute Treatment Agent. See the Preferred Drug List (PDL) for the list of preferred Migraine Acute Treatment Agents at: <https://papdl.com/preferred-drug-list>.
2. A Migraine Acute Treatment Agent with a prescribed quantity that exceeds the quantity limit. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.
3. A Migraine Acute Treatment Agent when there is a record of a recent paid claim for another Migraine Acute Treatment Agent in the point-of-sale on-line claims adjudication system (therapeutic duplication).
4. A prescription for a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant).
5. A prescription for a serotonin (5-HT) 1F receptor agonist (ditan).
6. A prescription for an ergot alkaloid.

B. Revisions to Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Migraine Acute Treatment Agent, the determination of whether the requested prescription is medically necessary will take into account the whether the beneficiary:

1. For a gepant for the preventive treatment of migraine, see the prior authorization guideline related to Migraine Prevention Agents; **OR**
2. **Both** of the following:
 - a. Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication
 - b. Has a diagnosis confirmed according to the current International Headache Society Classification of Headache Disorders;

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

AND

3. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
5. Does not have a contraindication to the prescribed drug; **AND**
6. For a gepant for the acute treatment of migraine, **one** of the following:
 - a. Has a history of therapeutic failure of at least two (5-HT_{1B/1D}) receptor agonists (triptans)
 - b. Has a contraindication or an intolerance to the preferred triptans;

AND

7. For a ditan, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred triptans; **AND**
8. For an ergot alkaloids, has a history of therapeutic failure of or a contraindication or an intolerance to standard first-line abortive drugs based on headache classification as recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society); **AND**
9. For a non-preferred Migraine Acute Treatment Agent, **one** of the following:
 - a. For a non-preferred triptan, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred triptans,
 - b. For a non-preferred gepant, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred gepants,
 - c. **For a non-preferred non-steroidal anti-inflammatory drug (NSAID) (e.g., Elyxyb [celecoxib] solution, diclofenac potassium powder packet), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred oral NSAIDs (excluding ketorolac) approved or medically accepted for the beneficiary's diagnosis in the NSAIDs Statewide PDL class,**
 - d. **For a non-preferred triptan-NSAID combination product, all of the following:**
 - i. **Has a history of therapeutic failure of or a contraindication or an intolerance to**

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

- the preferred triptans,
- ii. Has a clinical reason as documented by the prescriber why the individual active ingredients cannot be used concurrently,
 - iii. In addition, for Symbravo (meloxicam-rizatriptan), has a history of therapeutic failure of or a contraindication or an intolerance to sumatriptan-naproxen tablet,
- e. For non-preferred Migraine Acute Treatment Agents other than triptans, and gepants, NSAIDs, and triptan-NSAID combination products (e.g., ditans, ergot alkaloids, etc.), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication;

AND

10. For therapeutic duplication, **one** of the following:
- a. Is being titrated to or tapered from another drug in the same class
 - b. Has a medical reason for concomitant use of the requested drugs that is supported by peer-reviewed medical literature or national treatment guidelines;

AND

11. If a prescription for a Migraine Acute Treatment Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account **all** of the following:
- a. The guidelines set forth in the Quantity Limits Chapter,
 - b. Whether the beneficiary is prescribed the requested drug by **one** of the following:
 - i. A neurologist
 - ii. A headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS),
 - c. For the acute treatment of migraine, **both** of the following:
 - i. **One** of the following:
 - a) The beneficiary is using the requested drug in addition to at least one drug for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody, gepant, botulinum toxin)
 - b) The beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to all preventive migraine drugs recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology,

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

American Academy of Family Physicians, American Headache Society)

- ii. Has documentation of an evaluation for the overuse of abortive drugs, including opioids.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR A MIGRAINE ACUTE TREATMENT AGENT: The determination of medical necessity of a request for renewal of a prior authorization for a Migraine Acute Treatment Agent that was previously approved will take into account whether the beneficiary:

1. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
2. Does not have a contraindication to the prescribed drug; **AND**
3. Has documentation of improvement in headache pain, symptoms, or duration; **AND**
4. For a non-preferred Migraine Acute Treatment Agent, **one** of the following:
 - a. For a non-preferred triptan, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred triptans,
 - b. For a non-preferred gepant, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred gepants,
 - c. For a non-preferred NSAID (e.g., Elyxyb [celecoxib] solution, diclofenac potassium powder packet), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred oral NSAIDs (excluding ketorolac) approved or medically accepted for the beneficiary's diagnosis in the NSAIDs statewide PDL class,
 - d. For a non-preferred triptan-NSAID combination product, all of the following:
 - i. Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred triptans,
 - ii. Has a clinical reason as documented by the prescriber why the individual active ingredients cannot be used concurrently,
 - iii. In addition for Symbravo (meloxicam-rizatriptan), has a history of therapeutic failure of or a contraindication or an intolerance to sumatriptan-naproxen tablet,

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

- e. For non-preferred Migraine Acute Treatment Agents other than triptans, ~~and~~ gepants, **NSAIDs, and triptan-NSAID combination products** (e.g., ditans, ergot alkaloids, etc.), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication;

AND

- 5. For therapeutic duplication, **one** of the following:
 - a. Is being titrated to or tapered from another drug in the same class
 - b. Has a medical reason for concomitant use of the requested drugs that is supported by peer-reviewed medical literature or national treatment guidelines;

AND

- 6. If a prescription for a Migraine Acute Treatment Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account **all** of the following:
 - a. The guidelines set forth in the Quantity Limits Chapter,
 - b. Whether the beneficiary is prescribed the requested drug by **one** of the following:
 - i. A neurologist
 - ii. A headache specialist who is certified in headache medicine by the UCNS,
 - c. For the acute treatment of migraine, **both** of the following:
 - i. **One** of the following:
 - a) The beneficiary is using the requested drug in addition to at least one drug for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody, gepant, botulinum toxin)
 - b) The beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to all preventive migraine drugs recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society)
 - ii. Has documentation of an evaluation for the overuse of abortive drugs, including opioids.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Migraine Acute Treatment Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. References

1. (2021), 63rd Annual Scientific Meeting American Headache Society®. Headache: The Journal of Head and Face Pain, 61: 1-178. <https://doi.org/10.1111/head.14130>
2. Almotriptan Package Insert. North Wales, PA: Teva Pharmaceuticals USA, Inc.; May 2017.
3. American Headache Society. The American Headache Society position statement on integrating the new migraine treatments into clinical practice. Headache. 2019;59:1-18.
4. D.H.E. 45 Package Insert. Bridgewater, NJ: Bausch Health US, LLC; April 2022.
5. **Diclofenac potassium powder Package Insert. Fairfield, NJ: Leading Pharma, LLC; January 2024.**
6. **Elyxyb Package Insert. Raleigh, NC: BioDelivery Sciences International, Inc.; September 2021.**
7. Frova Package Insert. Malvern, PA: Endo Pharmaceuticals Inc.; August 2018.
8. Imitrex Package Insert. Durham, NC: GlaxoSmith-Kline; February 2024.
9. Institute for Clinical Systems Improvement. Diagnosis and treatment of headache. eleventh edition. January 2013.
10. International Headache Society. Headache Classification Committee of the International Headache Society (IHS): the international classification of headache disorders, 3rd edition. Cephalalgia. 2018; Vol. 38(1):1-211.
11. Mack KJ. Acute treatment of migraine in children. Patterson MC, Swanson JW, Goddeau Jr. RP, eds. Waltham, MA: UpToDate Inc. Updated May 08, 2023. Accessed August 19, 2024.
12. Maxalt Package Insert. Jersey City, NJ: Organon LLC; June 2021.
13. Mayans L, Walling A. Acute migraine headache: treatment strategies. American Family Physician. 2018;97(4):243-251.
14. Migranal Package Insert. Bridgewater, NJ: Bausch Health US, LLC; September 2022.
15. Naratriptan Package Insert. Princeton, NJ: Bionpharma Inc.; December 2023.
16. Nurtec ODT Package Insert. New York, NY: Pfizer Labs; ~~April 2023~~ **August 2025.**
17. Relpax Package Insert. New York, NY: Roerig Division of Pfizer Inc.; March 2020.
18. Reyvow Package Insert. Indianapolis, IN: Eli Lilly and Company; September 2022.
19. Schwedt TJ, Garza I. Acute treatment of migraine in adults. Swanson JW, Goddeau Jr. RP, eds. Waltham, MA: UpToDate Inc. Updated July 22, 2024. Accessed August 19, 2024.

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
MIGRAINE ACUTE TREATMENT AGENTS

20. **Symbravo Package Insert. New York, NY: Axsome Therapeutics, Inc.; February 2025.**
21. Tosymra Package Insert. Princeton, NJ: Promius Pharma, LLC; January 2019.
22. Treximet Package Insert. Brentwood, TN: Currax Pharmaceuticals LLC; ~~February~~
November 2024.
23. Trudhesa Package Insert. Milano, Italy: Mipharm, S.p.A.; August 2023.
24. Ubrelyv Package Insert. North Chicago, IL: AbbVie Inc.; June 2023 **2025.**
25. Zavzpret Package Insert. New York, NY: Pfizer Labs; ~~March 2023~~ **August 2025.**
26. Zembrace SymTouch Package Insert. Princeton, NJ: Promius Pharma; June 2019.
27. Zomig Package Insert. Bridgewater, NJ: Amneal Specialty; March 2022.